Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study - Concepedia

Concepedia

Publication | Open Access

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

DOI Full Paper Access

77

Citations

24

References

2021

Year

Qiyi Zhang, Xingyu Liu, Shumei Wei, Lufei Zhang, Yang Tian, Zhenzhen Gao, Ming Jin, Sheng Yan

Frontiers in Oncology

Abstract

www.chictr.org.cn, ChiCTR2100044476.

References

	Year	Citations
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Juan W. Valle, Harpreet Wasan, Daniel H. Palmer, New England Journal of Medicine	2010	4.3K
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle, Marwan Fakih, Juanita Lopez, The Lancet Oncology	2020	2.4K
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Journal of Clinical Oncology	2019	1.8K
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Journal of Clinical Oncology	2020	1.1K
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study Andrea Necchi, Andrea Anichini, Daniele Raggi, Journal of Clinical Oncology	2018	712
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno, International Journal of Cancer	2020	485
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer Janet E. Murphy, Jennifer Y. Wo, David P. Ryan, JAMA Oncology	2019	484
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models Osamu Tohyama, Junji Matsui, Kotaro Kodama, Journal of Thyroid Research Antitumor ActivityAngiogenesis InhibitorPathologyTumor BiologyTumor Angiogenesis	2014	468
Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma Kohei Shigeta, Meenal Datta, Tai Hato, Hepatology	2019	398

Page 1